Lysosomal Storage Disorder Therapeutics Exhibits Emerging Pipeline with 70+ Drug Candidates

The study analyzed that the lysosomal storage disorder therapeutics pipeline comprises approximately 74 drug candidates in different stages of development.

According to the research findings, most of the drug candidates for lysosomal storage disorder pipeline are being developed to be administered by intravenous route.

Browse Report Description at: https://www.psmarketresearch.com/market-analysis/lysosomal-storage-disorders-pipeline-analysis

Amicus Therapeutics, Inc. is using chaperone advanced replacement therapy (CHART) technology platform for the development of their drug candidates for the treatment of Fabry disease, a type of lysosomal storage disorder. In a chaperone-advanced replacement therapy, a unique pharmacological chaperone, binds to the infused therapeutic enzyme, stabilizing the enzyme in its properly folded and active form. This proposed CHART mechanism may allow for enhanced tissue uptake, greater lysosomal activity, more reduction of storage material, and lower immunogenicity compared to ERT alone.

The research also found that various companies use natural sources for the development of lysosomal storage disorder therapeutics pipeline. Protalix BioTherapeutics, Inc. is developing their drug candidates, obtained from a natural source, for the treatment of Fabry disease.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/lysosomal-storage-disorders-pipeline-analysis/report-sample

Some of the other key players developing drugs for the treatment of lysosome storage disorder include GlaxoSmithKline plc, Sanofi Genzyme, Amicus Therapeutics, Inc. and others.

BET Inhibitors Pipeline Exhibit an Emerging Pipeline with 35+ Drug Candidates

According to a new research report “Global Bromodomain and Extra-Terminal (BET) Inhibitors Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments”, published by P&S Market Research, BET inhibitors currently exhibit a strong pipeline with estimated 38 drug candidates.

Browse the Report Summary at: https://www.psmarketresearch.com/market-analysis/bet-inhibitors-pipeline-analysis

The study analyzed that the BET inhibitors pipeline comprised 38 drug candidates in different stages of development.

As per the findings of the research, most of the BET inhibitor pipeline drug candidates are being developed to be administered by oral route.

In BET inhibitors, IC50 value is measured as the concentration of drug at which 50% of the target is inhibited. IC50 is a pharmacokinetic measure; the lower the IC50 of drug candidate, the lesser the desired effect, and the less likelihood of the drug to have some off-target effect. Kd is known as dissociation constant of drug. It measures the rate of dissociation of the drug and its binding affinity. Birabresib (MK8628), a BET inhibitor by Merck & Co., has IC50 value of 100nM.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/bet-inhibitors-pipeline-analysis/report-sample

The research finds that different companies are collaborating for the development of BET inhibitors. In January 2017, ConverGene had entered into a sponsored research agreement with the University of Maryland, Baltimore to investigate the in vivo anti-leukemic effects of ConverGene’s lead BET inhibitor drug candidates, CG223 and CG250.

Some of the key players developing BET inhibitors are Resverlogix Corp., GlaxoSmithKline plc, Bristol-Myers Squibb Company, and others.

Uveitis Exhibits Emerging Pipeline with 30+ Drug Candidates

The study analyzed that the uveitis therapeutics pipeline comprises 33 drug candidates in different stages of development. Uveitis is a type of inflammatory disease that causes swelling and destroys eye tissues. Occurrence of this disease can result in slight reduction of vision or lead to complete vision loss. Uveitis occurs when the middle layer of the eyeball gets inflamed (red and swollen). This layer, known as the uvea, has many blood vessels that nourish the eye. Uveitis can damage vital eye tissue, even resulting in permanent vision loss.

Explore Report Description at: https://www.psmarketresearch.com/market-analysis/uveitis-therapeutics-pipeline-analysis

pSivida Corp. is using durasert technology platform for the development of Medidur for the treatment of uveitis. This technology platform is used to provide sustained, localized delivery of drugs to the back of the eye. Durasert products are developed with a drug core surrounded with one or more polymer layers, the permeability of those layers and other aspects of the design of the product, controls the rate and duration of the drug release. However, changing the elements of the design, can help in altering both the rate and duration of release to meet different therapeutic needs. The later generation durasert products and product candidates are injected at the target site, while early generations were surgically implanted.

Many companies are involved in the development of drugs for the uveitis therapeutics pipeline, with their products in different phases.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/uveitis-therapeutics-pipeline-analysis/report-sample

Some of the key players developing drugs for the treatment of uveitis include Aldeyra Therapeutics, Inc., EyeGate Pharmaceuticals, Inc., pSivida Corp. and others.

Spinal Muscular Atrophy Therapeutics Pipeline Analysis 2017 by P&S Market Research

The study analyzed that the therapeutics pipeline comprises approximately 16 drug candidates in different stages of development. Spinal muscular atrophy is defined as the inherited genetic disease that is characterized by a failure of nerve cells called motor neurons. Motor neurons are responsible to accept the nerve impulses transmitted from the brain to the spinal cord and transmit the impulses to the muscle with the help of peripheral nerves. The loss of motor neurons leads to muscle weakness in muscles that are closest to the trunk of the body such as back, hips and shoulders.

Browse Report Description at: https://www.psmarketresearch.com/market-analysis/spinal-muscular-atrophy-therapeutics-pipeline-analysis

Imago Pharmaceuticals, Inc. is using nucleic acid therapeutics technology platform for the treatment of spinal muscular atrophy. Nucleic acid therapeutics technology includes large and innovative class of drugs that can modulate the function of target ribonucleic acid, or RNA, to ultimately affect the production of disease-associated proteins. Nucleic acid therapeutics comprise of complex mixtures of various chemical entities known as stereoisomers. Some stereoisomers in these mixtures have therapeutic effects, while others are less beneficial or contribute to undesirable side effects. Uncontrolled stereoisomer drug mixtures can lead to suboptimal efficacy and increased risk and safety concerns.

The research also found that there are several companies that use synthetic sources for the development of drugs for the treatment of spinal muscular atrophy.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/spinal-muscular-atrophy-therapeutics-pipeline-analysis/report-sample

Some of the other key players developing drugs for the treatment of spinal muscular atrophy include Cytokinetics, Inc., F. Hoffman La-Roche Ltd, WAVE Life Sciences Ltd. and others.

Fibrin Glue Market Size, Share, Development, Growth and Demand Forecast to 2023

According to the study, the global fibrin glue market is likely to grow significantly during the forecast period, mainly due to increasing number of surgical procedures and burn cases, and rising healthcare expenditure. According to the data provided by the World Bank, 30,537 surgeries were performed per 100,000 population, in 2012, in the U.S. Similarly, in 2015, number of surgical procedures performed in Australia were 28,907 per 100,000 population. Fibrin glue is used in various types of surgeries. Fibrin glue is also used in burn cases during plastic surgeries and surgery of the burned body parts. According to WHO, approximately 265,000 deaths every year are caused by burns. Additionally, increasing prevalence of chronic diseases and low chances of complications associated with these products and rise in the number of road accidents also contributes to the growth of the overall market. However, increasing minimally invasive procedures and stringent regulatory requirements are some of the key factors restraining the growth of global fibrin glue market.

Browse Report Description at: https://www.psmarketresearch.com/market-analysis/fibrin-glue-market

Geographically, North America has been the largest market for fibrin glue, with the U.S. being the larger contributor to the regional market, compared to Canada. High prevalence of cardiovascular diseases is a key factor driving the growth of North America fibrin glue market for cardiac surgery. Additionally, the growth of the fibrin glue market in this region is driven by the rise in number of surgical procedures; especially plastic surgeries in the region, high expenditure on healthcare, increasing geriatric population, high number of road accidents and burn cases. According to American Heart Association (AHA), around 85.6 million people are living with cardiovascular diseases, in the U.S. According to Centers for Disease Control and Prevention (CDC), total national healthcare expenditure in the U.S. was $3.0 trillion in 2014 and per capita national health expenditure was $9,523. According to the American Society of Plastic Surgeons, around 14.6 million cosmetic plastic surgeries were carried out in the U.S. in 2012, which was 5% higher as compared to 2011. According to a United Nations publication, the population of people aged 60 years and above in North America was approximately 74.6 million in 2015, and the number is estimated to reach approximately 104.8 million by 2030. Thus, the demand for fibrin glue products is expected to increase in the region.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/fibrin-glue-market/report-sample

Cosmetic surgeries involve the restoration, reconstruction or alteration of the human body. These surgeries are witnessing popularity due to increasing consumer awareness and technological advancements in surgical procedures. Fibrin glue is used for these procedures to hold the tissues together. Due to increasing awareness about cosmetic procedures and increasing appearance consciousness, these procedures are gaining more popularity, thus causing a positive impact on the growth of the global fibrin glue market.

Key player in the fibrin glue market are extensively working on indication expansion of the existing fibrin glue products to leverage full potential of their products in various indications.

Some of the key players operating in the global fibrin glue market include Vivostat A/S, Kaketsuken, Johnson & Johnson, Baxter International Inc., CSL Behring, Zimmer Biomet Holdings, Inc., Takeda Pharmaceutical Company Limited, Mallinckrodt Plc, Shanghai RAAS Blood Products Co. Ltd. and Hualan Biological Engineering Inc.

HIV Diagnosis Market Size, Share, Development and Demand Forecast to 2023

According to the study, the global HIV diagnosis market is likely to grow significantly during the forecast period, due to rising prevalence of HIV/AIDS, increasing awareness with respect to blood donations and blood transfusions, and advantageous features of point of care instruments and kits are some of the key drivers for the global market growth. In addition, rising healthcare expenditure leading to improvement in healthcare infrastructure further contributes to the growth of the overall market. High cost of automated procedure and stringent regulatory requirements are some of the key factors restraining the global market growth.

Access Report Overview: https://www.psmarketresearch.com/market-analysis/hiv-diagnosis-market

Geographically, North America has been the largest market for HIV diagnosis, with the U.S. being the largest contributor to the regional market. Increasing prevalence of HIV/AIDS and advantageous features of point of care instruments and kits has been driving the growth of the North American market. In Europe, the U.K. has been the largest contributor to the market for HIV diagnosis, followed by Germany and France. The market is expected to witness the fastest growth in Asia-Pacific, during 2017 - 2023, owing to increasing cases of HIV rising healthcare expenditure and increasing blood transfusion.

The governments in different countries is investing significant portion of their GDP for healthcare development. Although, there are large variations among the healthcare spending of different countries, healthcare has been one of the primary focus for all the nations. Healthcare spending in the developed economies such as North America and Europe is considerably high in comparison to the developing countries. The lower spending in developing countries is primarily due to their low income per capita GDP. However, per capita healthcare spending in developing countries is increasing due to the increasing government initiatives. The increasing healthcare expenditure leads to the increased demand for effective diagnosis of HIV, thus driving the growth of the global market.

Request for Report Sample at: https://www.psmarketresearch.com/market-analysis/hiv-diagnosis-market/report-sample

Some of the key players in the global HIV diagnosis market include Siemens AG, Hoffman La Roche Ltd., Danaher Corporation, Abbott Laboratories, Ltd., Thermo-Fisher Scientific Inc., Merck KGaA, Becton, Dickinson & Company, Alere Inc., Bio-Rad Laboratories and Hologic Inc.

Rising Prevalence of Anaphylaxis to Drive the Global Auto-Injectors Market

According to the study, the global auto-injectors market is likely to grow significantly during the forecast period, due to increasing prevalence of anaphylaxis, increasing cases with multiple sclerosis, rising geriatric population and high production of biologics. Additionally, increasing healthcare spending and various beneficial features of auto-injectors also contribute to the growth of the overall market. However, high cost of auto-injectors and stringent regulatory requirements are some of the key factors restraining the growth of global auto-injectors market.

Explore Report Description at: https://www.psmarketresearch.com/market-analysis/auto-injectors-market

As per the findings of the research, the prefilled auto-injectors is the larger product category in the global auto-injectors market, primarily due to increasing availability of user friendly prefilled auto-injectors in disposable form. Based on manufacturing design, standardized auto-injector was the larger contributor to the global auto-injectors market in comparison to customized auto-injector in 2016. Anaphylaxis was the largest application for auto-injectors, followed by multiple sclerosis, rheumatoid arthritis and other diseases, in 2016. According to World Allergy Organization (WAO), the prevalence of anaphylaxis ranged from 2% of the population in the US, to 0.1% of the population in Korea, and 0.6% to 1% of the population in Australia.

Globally, the increasing demand for biologics has been playing a key role in the growth of the auto-injectors market. The rapidly increasing burden of anaphylaxis, multiple sclerosis, rheumatoid arthritis and other diseases further compels government organizations and healthcare providers to provide improved facilities for effective disease treatment, leading to rising number of launches of technologically advanced products, globally.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/auto-injectors-market/report-sample

Most of the biologics, such as monoclonal antibodies, anticoagulants, and vaccines are large molecules which need to be administered parenterally to achieve the desired therapeutic effects. The demand for development of injectable biologic therapies is increasing, since many peptides break down too quickly in the stomach and after which they no longer remain useful for treatment. Also, various biologic drugs and vaccines require to be injected directly into the bloodstream. The introduction of biosimilars would enforce the usage of injectable in auto-injectors, and thus the consumption and demand of auto-injectors is expected to increase.

Some of the key players operating in the global auto-injectors market include Mylan N.V., Antares Pharma Inc., Becton, Dickinson & Co., Eli Lilly and Company, Pfizer, Inc., Bayer AG, Novartis International AG, Bristol-Myer Squibb, Novartis AG, Amgen Inc. and Biogen Inc.